Jade Biosciences, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On June 29, 2026, Paragon Therapeutics licensed to Jade Biosciences exclusive rights to develop, manufacture, and commercialize antibodies targeting interferon-beta (IFN-β) worldwide. Jade will pay Paragon up to $22,000,000 in development milestones (ranging from $1.5M at Development Candidate to $10M at FDA approval), tiered royalties on net sales (rates redacted but capped when no valid patent claims exist), and reimbursement of certain sublicense fees. The license covers Licensed Antibodies, Derived Antibodies, and Multispecific Antibodies, with Paragon retaining limited rights to develop competing multispecific formats subject to Jade's right-of-first-negotiation.
Why this rating
Routine licensing deal for early-stage antibody program. Milestone payments totaling $22M (~7.6% of company's $289M market cap) are material but typical for preclinical/early clinical assets. No revenue impact yet; clinical risk high. Standard terms; no business transformation.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.